Latest Insider Transactions at Black Diamond Therapeutics, Inc. (BDTX)
This section provides a real-time view of insider transactions for Black Diamond Therapeutics, Inc. (BDTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Black Diamond Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Black Diamond Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2022
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
5,850
+27.33%
|
$11,700
$2.03 P/Share
|
|
Apr 28
2022
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
255,711
+5.17%
|
$511,422
$2.57 P/Share
|
|
Apr 27
2022
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
150,000
+3.27%
|
$300,000
$2.66 P/Share
|
|
Apr 19
2022
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
150,000
+3.38%
|
$450,000
$3.24 P/Share
|
|
Apr 18
2022
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
150,000
+3.5%
|
$450,000
$3.29 P/Share
|
|
Apr 13
2022
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
102,556
+2.51%
|
$307,668
$3.57 P/Share
|
|
Apr 12
2022
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
150,000
+3.72%
|
$450,000
$3.42 P/Share
|
|
Mar 18
2022
|
Mark A. Velleca PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,897
+50.0%
|
$8,691
$3.02 P/Share
|
|
Mar 18
2022
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
5,795
+23.95%
|
$17,385
$3.02 P/Share
|
|
Mar 18
2022
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
4,346
+30.93%
|
$13,038
$3.02 P/Share
|
|
Feb 15
2022
|
Erika Jones |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+50.0%
|
-
|
|
Dec 17
2021
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
3,296
+20.73%
|
$16,480
$5.31 P/Share
|
|
Dec 17
2021
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
2,472
+31.57%
|
$12,360
$5.31 P/Share
|
|
Sep 17
2021
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
1,869
+16.72%
|
$16,821
$9.9 P/Share
|
|
Sep 17
2021
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
1,326
+31.47%
|
$11,934
$9.9 P/Share
|
|
Jun 18
2021
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
1,255
+14.44%
|
$15,060
$12.95 P/Share
|
|
Jun 18
2021
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
1,014
+39.38%
|
$12,168
$12.95 P/Share
|
|
May 20
2021
|
Rajeev M. Shah |
SELL
Other acquisition or disposition
|
Direct |
443
-100.0%
|
$10,632
$24.01 P/Share
|
|
May 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-12.0%
|
$110,106
$27.4 P/Share
|
|
May 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
May 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-43.86%
|
$65,000
$26.64 P/Share
|
|
May 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Apr 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-32.68%
|
$101,950
$25.0 P/Share
|
|
Apr 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
Apr 05
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-43.86%
|
$62,500
$25.54 P/Share
|
|
Apr 05
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Apr 01
2021
|
Rajeev M. Shah |
BUY
Other acquisition or disposition
|
Indirect |
353,814
+13.44%
|
$8,491,536
$24.26 P/Share
|
|
Mar 18
2021
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
677
+9.87%
|
$16,248
$24.01 P/Share
|
|
Mar 18
2021
|
Rajeev M. Shah |
BUY
Grant, award, or other acquisition
|
Direct |
443
+50.0%
|
$10,632
$24.01 P/Share
|
|
Mar 18
2021
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
547
+50.0%
|
$13,128
$24.01 P/Share
|
|
Mar 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-32.68%
|
$106,028
$26.36 P/Share
|
|
Mar 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
Mar 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-25.0%
|
$65,000
$26.21 P/Share
|
|
Mar 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Feb 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-16.87%
|
$110,106
$27.43 P/Share
|
|
Feb 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
Feb 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-43.86%
|
$62,500
$25.35 P/Share
|
|
Feb 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Jan 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
11,578
-11.49%
|
$370,496
$32.49 P/Share
|
|
Jan 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
11,578
+25.96%
|
$81,046
$7.03 P/Share
|
|
Jan 08
2021
|
Thomas Leggett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-100.0%
|
$99,000
$33.94 P/Share
|
|
Jan 08
2021
|
Thomas Leggett Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
$30,000
$10.86 P/Share
|
|
Jan 04
2021
|
David M. Epstein |
SELL
Open market or private sale
|
Direct |
12,000
-0.85%
|
$372,000
$31.4 P/Share
|
|
Jan 04
2021
|
David M. Epstein |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.42%
|
$18,000
$6.42 P/Share
|
|
Jan 04
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-24.4%
|
$77,500
$31.55 P/Share
|
|
Jan 04
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Dec 28
2020
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
5,400
+39.13%
|
$16,200
$3.2 P/Share
|
|
Dec 15
2020
|
David M. Epstein |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.35%
|
$15,000
$6.42 P/Share
|
|
Dec 15
2020
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+50.0%
|
$32,000
$10.86 P/Share
|
|
Dec 15
2020
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
505
+8.4%
|
$17,170
$34.29 P/Share
|